MedC Biopharma

Cannabis-based Cancer Treatment

Health Tech & Life Sciences
Non Active, Mar 2023 ceased to operate

Company Overview

Snapshot

Founded in July 2016 by Avi Drori and Guy Drori, MedC Biopharma operated with 11–50 employees. The company raised $5 million across one funding round. In January 2021, MedC Biopharma partnered with Sana Healthcare to advance its skin oncology platform.

Business overview

MedC Biopharma is a clinical-stage company focused on developing novel cannabis-based treatments for various medical conditions, primarily targeting cutaneous T-cell lymphoma, a type of skin cancer. The company's R&D efforts are a collaboration with leading research institutions in Israel, and its pipeline includes additional skin oncology and anxiety-related indications. Operating within the Health Tech & Life Sciences sector, specifically Pharma & Medical Biotechnology and Medical Cannabis, MedC Biopharma serves the pharmaceutical market with its drug development and topical treatment products.

Strategic signal

In January 2021, MedC Biopharma announced a partnership with Sana Healthcare to advance its skin oncology platform. This collaboration signals a strategic move to accelerate the development and potential commercialization of its cannabis-based treatments for skin cancer, indicating a focus on leveraging external expertise to bring its product pipeline to market.

Company Intelligence Q&A

What is MedC Biopharma's primary focus?
MedC Biopharma is a clinical-stage company developing a novel cannabis-based treatment for cutaneous T-cell lymphoma, a type of skin cancer. Its R&D pipeline also includes additional skin oncology and anxiety-related indications.
Who founded MedC Biopharma?
MedC Biopharma was co-founded by Avi Drori, who serves as CEO and Chairman, and Guy Drori, who is the General Manager.
What significant research was published by MedC Biopharma?
In June 2020, the ARO Volcani Centre, in collaboration with Rabin Medical Centre and MedC Biopharma Corporation, announced the publication of its research in the peer-reviewed scientific journal Oncotarget.
What was a key strategic partnership for MedC Biopharma?
In January 2021, MedC Biopharma partnered with Sana Healthcare to advance its skin oncology platform, aiming to further develop its treatments for skin cancer.
What was the company's status as of March 2023?
MedC Biopharma ceased to operate in March 2023.

External links